FDA Clearance Tracker · P130008-S090
Inspire Upper Airway Stimulation System
Last checked: Nov 20, 2026Latest source record: Jun 8, 2023 (this decision)Source: openFDAMethods & limitations
Decided
Jun 8, 2023
Approved
Time to decision
234 days
Received Oct 17, 2022. Calendar days, including time FDA spent waiting on the applicant.
Pathway
PMA supplement
Panel Track
Device class
Class III
The decision
- FDA number
- P130008-S090
- Device name
- Inspire Upper Airway Stimulation System
- Applicant
- Inspire Medical Systems
- Applicant location
- Maple Grove, MN
- Received
- Oct 17, 2022
- Decided
- Jun 8, 2023
- Decision
- Approved
- Supplement type
- Panel Track
- Reason for supplement
- Labeling Change - Indications/instructions/shelf life/tradename
- Original approval
- P130008
Device type
- Device class
- Class III
FDA's approval statement
As written in FDA's record.
Approval to expand the indications for use to OSA patients with an upper limit baseline apnea-hypopnea index (AHI) to 100 (increase from <= 65 to <=100) and increasing the an upper limit body mass index (BMI) warning to 40 (increase from <=32 to <=40).
Source documents
Other decisions for Inspire Medical Systems
Matched on the applicant name as FDA recorded it. A company that files under several names will have more.
- Inspire Upper Airway StimulationPMA supplement
P130008-S089 · Decided Mar 20, 2023 · 213 days after receipt · Panel Track
Device type: Stimulator, hypoglossal nerve, implanted, apnea (MNQ) · Anesthesiology & Respiratory
1 more FDA decisions with a free account
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.